Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Leite, Marcelo S ^a,b   Giacomin, Letícia C ^a   Piranda, Diogo N ^a,c   Festa Vasconcellos, Juliana S ^a,c   Indio do Brasil, Vanessa ^a,b,c   Koifman, Sérgio ^d   de Moura Neto, Rodrigo S ^c,e   de Carvalho, Marcelo A ^a,f   Vianna Jorge, Rosane ^a,c,d  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

^f Instituto Federal Do Rio de Janeiro   (Brazil)

Author keywords

Breast cancer; EGFR; Gene expression; Gene polymorphisms; Prognostic estimates

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER; EGFR PROTEIN, HUMAN; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BRAZILIAN; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HISTOPATHOLOGY; HUMAN; INTRON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; RECURRENCE RISK; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; BRAZIL; BREAST TUMOR; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; PROGNOSIS; CANCER CLASSIFICATION; CLINICAL FEATURE; GENE DUPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN TISSUE; MUTATION RATE;

ADULT; AGED; AGED, 80 AND OVER; BRAZIL; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENETIC VARIATION; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899146826     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-190     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
2. Sørlie T, Perou CM, Tibshiranie R, Aasf T, Geislerg S, Johnsenb H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008, 107:309-330. 10.1007/s10549-007-9556-1, 2217620, 17377838.
4. Danova M, Delfanti S, Manzoni M, Mariucci S. Tissue and soluble biomarkers in breast cancer and their applications: ready to use?. J Natl Cancer Inst Monogr 2011, 2011:75-78. 10.1093/jncimonographs/lgr023, 22043046.
5. Ruiz C, Tolnay M, Bubendorf L. Application of personalized medicine to solid tumors: opportunities and challenges. Swiss Med Wkly 2012, 142:w13587.
6. Chung CC, Chanock SJ. Current status of genome-wide association studies in cancer. Hum Genet 2011, 130:59-78. 10.1007/s00439-011-1030-9, 21678065.
7. Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K, Buerger H. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res 2006, 12:7252-7260. 10.1158/1078-0432.CCR-06-0626, 17189396.
8. Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10-year follow-up study. Breast Cancer Res Treat 1994, 29:73-83. 10.1007/BF00666183, 8018964.
9. Flynn JF, Wong C, Wu JM. Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer. J Oncol 2009, 16.
10. Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008, 8:129-138. 10.1038/sj.tpj.6500444, 17375033.
11. Gebhardt F, Zänker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999, 274:13176-13180. 10.1074/jbc.274.19.13176, 10224073.
12. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, Lelle R, Boecker W, Brandt B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000, 60:854-857.
13. Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci 1994, 91:10217-10221. 10.1073/pnas.91.21.10217, 44989, 7937865.
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting Recommendations for Tumor Marker Prognostic Studies. J Clin Oncol 2005, 23(36):9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
15. Lester S, Bose S, Chen Y, Connolly J, de Baca M, Fitzgibbons P, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 2009, 133:1515-1538.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
17. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010, 124:133-140. 10.1007/s10549-010-1103-9, 20697801.
18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
19. Gonçalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, Monges G, Bertucci F, Esterni B, Delpero JR, Turrini O, Lelong B, Viens P, Borg JP, Birnbaum D, Olschwang S, Viret F. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 2008, 8:169. 10.1186/1471-2407-8-169, 2432064, 18544172.
20. McKibbin T, Zhao W, Tagen M, Daw NC, Furman WL, McGregor LM, Geyer JR, Allen JW, Stewart CF. Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. Eur J Cancer 2010, 46:2045-2051. 10.1016/j.ejca.2010.05.007, 2904359, 20621735.
21. Liu W, Innocenti F, Chen P, Das S, Cook EH, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003, 9:1009-1012.
22. Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 2007, 4:e125. 10.1371/journal.pmed.0040125, 1876407, 17455987.
23. Sasaki H, Okuda K, Shimizu S, Takada M, Kawahara M, Kitahara N, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Kubo A, Kawano O, Yukiue H, Yano M, Fujii Y. EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol 2009, 135:313-318. 10.1007/s00432-008-0464-5, 18726117.
24. Huang C-L, Yang C-H, Yeh K-H, Hu F-C, Chen K-Y, Shih J-Y. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 2009, 64:346-351. 10.1016/j.lungcan.2008.09.009, 18995924.
25. Zhou Q, Cheung Y, Jada S, Lim W, Kuo W, Gray J, Lee AS, Chowbay B. EGFR Intron 1 polymorphism in Asian populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol Ther 2006, 5:1445-1449. 10.4161/cbt.5.11.3457, 17102595.
26. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Cusati G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004, 64:9139-9143. 10.1158/0008-5472.CAN-04-1036, 15604284.
27. Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, Isola J, Yatabe Y, Nakachi K, Boecker W, Brandt B. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence-first results of an inter-ethnic breast cancer study. J Pathol 2004, 203:545-550. 10.1002/path.1542, 15095477.
28. Buisine M-P, Wacrenier A, Mariette C, Leteurtre E, Escande F, Aissi S, Ketele A, Leclercq A, Porchet N, Lesuffleur T. Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers. World J Gastroenterol 2008, 14:1053-1059. 10.3748/wjg.14.1053, 2689408, 18286687.
29. Etienne-Grimaldi M-C, Pereira S, Magné N, Formento J-L, Francoual M, Fontana X, Demard F, Dassonville O, Poissonnet G, Santini J, Bensadoun RJ, Szepetowski P, Milano G. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 2005, 16:934-941. 10.1093/annonc/mdi189, 15829495.
30. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH, Ratain MJ. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005, 65:46-53.
31. Gömöri E, Pál J, Kovács B, Dóczi T. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Diagn Pathol 2012, 7:8. 10.1186/1746-1596-7-8, 3292961, 22264301.
32. Kallel I, Rebai M, Khabir A, Farid NR, Rebaï A. Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia. J Biomed Biotechnol 2009, 2009:753683. 2711625, 19636371.
33. Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be considered for incorporation into staging for breast cancer. Ann Surg Oncol 2011, 18:3143-3148. 10.1245/s10434-011-2012-9, 21847696.
34. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 1999, 79:1564-1571. 10.1038/sj.bjc.6690249, 2362699, 10188907.
35. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, David D, Schlaepfer DD, Hanks SK, Cheresh DA. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 2010, 69:1383-1391.
36. Hudson L, Moss N, Stack M. EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. Future Oncol 2009, 5:323-338. 10.2217/fon.09.10, 2709955, 19374540.
37. Fox EM, Andrade J, Shupnik MA. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 2009, 74:622-627. 10.1016/j.steroids.2008.10.014, 2702758, 18996136.
38. Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 2011, 16:276-285. 10.1634/theoncologist.2010-0302, 3228102, 21339261.
39. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005, 97:1254-1261. 10.1093/jnci/dji249, 16145046.
40. Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, Yun J, Press OA, Vallböhmer D, Rhodes K, Lenz HJ. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 2005, 11:600-605.
41. Bandrés E, Barricarte R, Cantero C, Honorato B, Malumbres R, Zárate R, Alcalde J, García-Foncillas J. Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. Oral Oncol 2007, 43:713-719. 10.1016/j.oraloncology.2006.09.002, 17112774.
42. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz HJ. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res 2008, 68:3037-3042. 10.1158/0008-5472.CAN-07-2718, 18413774.
43. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: Pathogenesis and clinical implications. Mol Oncol 2010, 4:255-266. 10.1016/j.molonc.2010.04.001, 2904860, 20434415.